MEDIA RELEASE

QT VASCULAR SECURES US$12 MILLION OF CONVERTIBLE BONDS FUNDING

Highlights:

- **Proceeds to be used to position QT Vascular for the next phase of growth**
- **Various investors will subscribe to convertible bonds for a principal amount of US$12 million with a two-year maturity period**
- **Reflects the confidence in QT Vascular's Chocolate® platform**

SINGAPORE, 1 July 2015 – QT Vascular Ltd., together with its subsidiaries ("**QT Vascular**" or the "**Group**"), a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease, has entered into a convertible bond subscription agreement ("**Agreement**") with ICH Gemini Asia Growth Fund Pte Ltd ("**ICH Gemini**") and three other individual investors for a US$12 million convertible bond investment. This funding will strengthen the Group's financial position needed to propel it to the next milestone by allowing the Group to focus more resources on developing its Drug Coated Chocolate® platform further.

Dr. Eitan Konstantino, Ph.D., Chief Executive Officer of QT Vascular said, ***"We are extremely excited to receive funding support from such established investors. This reflects the confidence they have in our business, our products and our prospects. ICH Gemini and the individual investors' investment will allow us to realise our milestones faster and together, we can move forward towards the next growth trajectory."***

On its decision to invest in QT Vascular, Mr Vincent Toe, Director of ICH Gemini commented, ***"We are happy to be a part of QT Vascular's growth, to be able to help lift the Group to the next milestone. We are impressed with the Group's ability in achieving its milestones, its deep industry knowledge and its committed management team. We look forward to QT Vascular's growth as it develops its unique, low-trauma Chocolate® platform."***

The 8% coupon convertible bonds will have a two-year maturity period and can be converted into ordinary shares at S$0.192 per share based on and subject to the terms of the Agreement. The conversion price of S$0.192 per share represents a 8.5% premium over QT Vascular's closing price of S$0.177 on 30 June 2015. This also indicates the level of confidence the investors have in QT Vascular's Chocolate® platform. The bonds can be converted at any time at the sole discretion of the investors based on and subject to the terms of the Agreement.

The conversion and/or redemption price in the event of either (i) sale of QT Vascular and/or all or any of its subsidiaries or (ii) sale of a major asset or business of the Group, at a price equal to or more than S$100.0 million, within the two-year maturity period (the "**Qualifying Exit Event**") shall be determined based on the conditions set out in the agreement, depending on when the Qualifying Exit Event occurs.

The Group has an unaudited net cash balance of US$9.7 million as at 31 March 2015. With the investors' support, QT Vascular would be able to focus more resources on developing its unique Chocolate® angioplasty balloon platform further, as it works towards obtaining the necessary regulatory approvals, particularly the Food and Drug Administration ("**FDA**") approval. With the necessary approvals, the Group will be able to realise the strong potential of its Chocolate® platform. By lowering acute trauma, Chocolate® has been able to minimize flow-limiting dissections, therefore reducing the need for unplanned stenting in the peripheral arteries as compared to conventional balloons. Its Chocolate® PTA Balloon Catheter, was the first medical interventional product from Singapore to receive the US FDA clearance. The Chocolate® platform is also used to treat patients' coronary arteries.

Healthcare spending across the globe is rising, particularly on innovative solutions that can improve lives and be administered efficiently. This is underpinned by a global ageing population, rising income levels in developing economies and expanding insurance coverages. Pharmaceutical and healthcare-related companies with products that can improve clinical outcomes and lower overall healthcare costs will benefit from this trend.

About ICH Gemini

ICH Gemini Asia Growth Fund is a private equity fund managed by ICH Gemini Pte Ltd.

~~ End ~~

This press release is to be read in conjunction with the Company's announcement posted on the SGX website on 1 July 2015

ABOUT QT VASCULAR LTD. (SGX Stock code: 5I0 | Bloomberg: QTVC:SP | Reuters: QTVA:SI)

QT Vascular Ltd. together with its subsidiaries ("**QT Vascular**" or the "**Group**"), is an emerging leader in the development and commercialization of next generation minimally invasive products for the treatment of complex vascular disease. QT Vascular works closely with leading physicians and scientists from around the world to create differentiated devices that improve procedural and clinical outcomes.

QT Vascular is based in Singapore with a US subsidiary, TriReme Medical LLC ("**TriReme Medical**"), based in Pleasanton, California. TriReme Medical's range of percutaneous transluminal angioplasty ("**PTA"**) and percutaneous transluminal coronary angioplasty ("**PTCA**") products include (i) Chocolate® PTA Balloon Catheter, (ii) Chocolate® PTCA Balloon Catheter, (iii) GliderXtreme™ PTA Balloon Catheter, (iv) GliderfleX® PTA Balloon Catheter and (v) Glider™ PTCA Balloon Catheter, all of which have the CE Mark that allows them to be sold in Europe, and FDA clearance to be sold in the United States. Additionally, the GliderXtreme™ PTA Balloon Catheter has the regulatory clearance in China and Japan, while the Glider™ PTCA Balloon Catheter has the regulatory clearance in Japan. These products are sold through its main distributors: (i) Cordis Corporation (a wholly-owned subsidiary of Johnson & Johnson), (ii) Shandong Weigao Group Medical Polymer Co Ltd and (iii) Century Medical, Inc.

The Group is also applying for CE marking approval with respect to the Chocolate® Touch, its advanced drug-coated peripheral balloon.

In October 2014, the Group acquired a novel technology platform called Java, and all its associated intellectual property. The Group believes the Java technology is a strong fit with QT Vascular's core expertise in minimally invasive angioplasty.

For more information, please visit the company website at www.qtvascular.com

Issued on behalf of **QT VASCULAR LTD.** by:

WATERBROOKS CONSULTANTS PTE LTD
Tel: +65 6100 2228

For media and analysts, please contact:

Mr Wayne Koo	(M): +65 9338 8166	wayne.koo@waterbrooks.com.sg
Ms Lynette Tan	(M): +65 9687 2023	lynette@waterbrooks.com.sg
Ms Angeline Cheong	(M): +65 9666 0977	angeline@waterbrooks.com.sg

Cautionary Note on Forward-Looking Statements

All statements other than statements of historical facts included in this announcement are or may be forward-looking statements. Forward-looking statements include but are not limited to those using words such as "expect", "anticipate", "believe", "estimate", "intend", "project", "plan", "strategy", "forecast" and similar expressions or future or conditional verbs such as "if", "will", "would", "should", "could", "may" and "might". These statements reflect the Company's current expectations, beliefs, hopes, intentions or strategies regarding the future and assumptions in light of currently available information. Such forward-looking statements are not guarantees of future performance or events and involve known and unknown risks and uncertainties. Accordingly, actual results may differ materially from those described in such forward-looking statements. Shareholders should not place undue reliance on such forward-looking statements, and the Company undertakes any obligation to update publicly or revise any forward-looking statements, subject to compliance with all applicable laws and regulations and/or the rules of the SGX-ST and/or any other regulatory or supervisory body or agency.

QT Vascular Ltd. (the "Company") was listed on Catalist board of the Singapore Exchange Securities Trading Limited (the "SGX-ST") on 29 April 2014. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor").

This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship, at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone +65 6229 8088.